Preeclampsia Laboratory Testing Market
Global Industry Analysis (2017 – 2019) – Growth Trends and Market Forecast (2020 – 2025)
All interactions and sensitive information remain confidential.
Custom Research Service
Undertaking exclusive research tailored for your business needs.
Demand for Preeclampsia Laboratory Testing to Witness Healthy Double Digit Revenue Growth by 2025 End
The global preeclampsia laboratory testing market registered revenues worth US$1242.9 Mn in 2020 and is set to exhibit robust revenue growth between 2020 and 2025. The market is poised to benefit from high prevalence of preeclampsia prominently in low and middle-income countries, coupled with new product launches that have been observed over the recent past.
A sizeable number of maternal deaths in the US are accounted by preeclampsia, which is the third most common cause of maternal mortality in the country. Across Africa and some of Asian countries, almost one in 10 deaths is related to hypertension in pregnancy. While these deaths are preventable with the help of early and proper diagnosis and the following patient care, it is necessary to increase awareness about the same among general population.
With gradually rising rate of awareness about eclampsia and preeclampsia, coupled with an improved early diagnosis rate, the market is expected to see a highly progressive outlook over the foreseeable future. Fairfield Market Research indicates that the valuation of global preeclampsia laboratory testing market will rise at healthy 10.2% CAGR during the period of assessment, reaching US$2,021.1 Mn by the end of 2025.
Growing Health & Economic Burden in Developed World Enhances Scope for Growth of Preeclampsia Laboratory Testing Market
The number of preeclampsia laboratory tests is on the rise in line with high prevalence, particularly in developing economies. As per Ethiopian National Emergency Obstetric and Newborn Care, about 10% of all maternal mortality (direct and indirect) is due to preeclampsia. In India, the incidence of preeclampsia is reported as high as 8-10% amongst the pregnant women.
On the other hand, the developed world is facing a severe challenge of growing health and economic burden. Preeclampsia Foundation states that short-term medical cost associated with preeclampsia is around $2.18 billion to the U.S. healthcare system. The cost after the first 12 months of delivery is $1.03 billion, for maternal healthcare and $1.15 billion for infants born to mothers with preeclampsia.
New Product Introductions and Research Partnerships Augment Supply of Novel Diagnostic Products
New product launches and research collaborations are taking place in the preeclampsia diagnostics landscape at fast pace. In early 2019, DiabetOmics, a U.S. based medical diagnostic company has launched a rapid point-of-care test named Lumella that provides an estimate of Glycosylated Fibronectin (GlyFN) - a protein biomarker elevated in pregnant women with high risk of developing preeclampsia. In June 2020, Ferring Pharmaceuticals and Igenomix have announced a research collaboration with a common objective of developing innovative diagnostic and therapeutic strategies for preeclampsia. Women's health diagnostic firm Progenity recently announced the launch of preeclampsia rule-out test, called preecludia, which is also expected to be commercialised in the latter half of 2021.
Despite High Prevalence Rate, Low Awareness Levels Continue to Forestall Rapid (Potential) Market Growth
Multiple challenges exist in dealing with preeclampsia in developing world – delayed decision making, delayed healthcare access, delayed healthcare delivery, deficient policy guidelines, and inadequate implementation at macro and micro levels. The severity of the impact is more in developing countries, where (unlike other more prevalent causes of maternal mortality, such as haemorrhage and sepsis), medical interventions may be ineffective solely due to late diagnosis of preeclampsia cases. Relative lack of awareness and inadequacy of reliable and cost-effective screening tests for preeclampsia, especially in developing economies, continue to hinder the growth of preeclampsia laboratory testing market.
Blood Tests Remain Sought-after among All Test Categories
Blood tests are the leading test type category and the same trend will continue through the forecast period. The dominance of blood tests over urine tests is due to preference for blood tests are on the rise due to comparatively high accuracy against conventional urine tests. Novel biomarkers are also hitting the market big time as is observed over the recent past.
Market to See Phenomenal Growth in Asia Pacific; North America Retains Dominance
Preeclampsia laboratory testing study reveals that Asia Pacific has maintained its high-growth potential and will demonstrate the same till the end of forecast year 2025. Highly populous countries such as India and China are witnessing high incidence rates for preeclampsia. A study published in the Pregnancy Hypertension journal (October 2019) reveals that the prevalence of preeclampsia in China has risen from 5.79% in 2005 to 9.50% in 2019.
North America remains the largest revenue contributor in global market owing to strong presence and initiatives of several government and patient advocacy groups formed for the development of better diagnostics regimen. The North American market was valued at US$ 465.6 Mn in 2020 and by the end of 2025, will exhibit a promising CAGR of 9.6%. In 2019, the US Food & Drug Association (FDA) has granted clearance to an advanced prenatal therapeutics (APT) breakthrough device designation for Targeted Apheresis Column for Preeclampsia (TAC-PE). APT's novel device specifically removes disease-causing factors from the mother's blood.
Competition Landscape of Preeclampsia Laboratory Testing Market Remains Concentrated
A few industry giants are capturing a significant proportion of global preeclampsia laboratory testing market. PerkinElmer, Inc., F. Hoffmann-La Roche AG, and ThermoFischer Scientific, the three biggest market players in terms of revenue generation, currently capture more than 60% of the global market.
The report also profiles and offers insights about some other prominent industry players, including Sera Prognostics, Inc., Bayer AG, Siemens Healthineers AG, Metabolomic Diagnostics Ltd., Diabetomics, Inc., DRG Instruments GmbH, and Progenity, Inc.